| pubmed-article:15812834 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15812834 | lifeskim:mentions | umls-concept:C0279000 | lld:lifeskim |
| pubmed-article:15812834 | lifeskim:mentions | umls-concept:C0600521 | lld:lifeskim |
| pubmed-article:15812834 | lifeskim:mentions | umls-concept:C0450363 | lld:lifeskim |
| pubmed-article:15812834 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:15812834 | pubmed:dateCreated | 2005-5-5 | lld:pubmed |
| pubmed-article:15812834 | pubmed:abstractText | The purpose of the current study was to evaluate the tolerance and efficacy of hypofractionated three-dimensional conformal radiotherapy (3DCRT) with or without transarterial chemoembolization (TACE) for technically unresectable or medically inoperable primary liver carcinoma (PLC). | lld:pubmed |
| pubmed-article:15812834 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15812834 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15812834 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:15812834 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15812834 | pubmed:month | May | lld:pubmed |
| pubmed-article:15812834 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:15812834 | pubmed:author | pubmed-author:JiangGuo-Lian... | lld:pubmed |
| pubmed-article:15812834 | pubmed:author | pubmed-author:FuXiao-LongXL | lld:pubmed |
| pubmed-article:15812834 | pubmed:author | pubmed-author:ChenLongL | lld:pubmed |
| pubmed-article:15812834 | pubmed:author | pubmed-author:ZhuXiao-DongX... | lld:pubmed |
| pubmed-article:15812834 | pubmed:author | pubmed-author:WangAn-YuAY | lld:pubmed |
| pubmed-article:15812834 | pubmed:author | pubmed-author:LiangShi-Xion... | lld:pubmed |
| pubmed-article:15812834 | pubmed:author | pubmed-author:LuHai-JieHJ | lld:pubmed |
| pubmed-article:15812834 | pubmed:author | pubmed-author:PanChao-YangC... | lld:pubmed |
| pubmed-article:15812834 | pubmed:author | pubmed-author:LiFu-XiangFX | lld:pubmed |
| pubmed-article:15812834 | pubmed:author | pubmed-author:HuangQi-FangQ... | lld:pubmed |
| pubmed-article:15812834 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15812834 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:15812834 | pubmed:volume | 103 | lld:pubmed |
| pubmed-article:15812834 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15812834 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15812834 | pubmed:pagination | 2181-8 | lld:pubmed |
| pubmed-article:15812834 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:meshHeading | pubmed-meshheading:15812834... | lld:pubmed |
| pubmed-article:15812834 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15812834 | pubmed:articleTitle | Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. | lld:pubmed |
| pubmed-article:15812834 | pubmed:affiliation | Department of Radiation Oncology, Cancer Hospital, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. | lld:pubmed |
| pubmed-article:15812834 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15812834 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15812834 | lld:pubmed |
